NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target
International Journal of Biological Sciences · 2024
DOI: 10.7150/ijbs.100188 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Shaoping Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma, Microtubule-Associated Proteins, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Nucleolar and spindle-associated protein 1 (NUSAP1), a microtubule-associated protein, has been recently identified to exhibit aberrant expression patterns that correlate with malignant tumorigenesis and progression across various cancer types. However, the specific regulatory mechanisms and potential targeting therapies of NUSAP1 in lung adenocarcinoma (LUAD) remain largely elusive. In this study, by conducting bioinformatics analyses as well as in vitro and in vivo experiments, we identified that NUSAP1 was significantly upregulated in LUAD, with a notable correlation with poorer overall survival, higher scores for immunogenicity and immune infiltration, as well as increased sensitivity to conventional chemotherapeutic drugs such as paclitaxel, docetaxel and vinorelbine in LUAD. Functionally, NUSAP1 overexpression significantly promoted LUAD cell proliferation, while its knockdown markedly suppressed this process. Interestingly, our results revealed that NUSAP1 upregulation was mediated by estrogen via ERβ activation. Furthermore, we identified entinostat as a novel inhibitor of NUSAP1. Pharmacological targeting ERβ/NUSAP1 axis with fulvestrant (ERβ antagonist) or entinostat (novel NUSAP1 inhibitor) significantly reduced LUAD growth both in vitro and in vivo, which may represent effective alternative therapeutic strategies for patients with LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
- Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangz…
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
- Department of Breast Surgery, the Sixth Affiliated Hospital of South China University of Technology, the Sixth Clinical College of South China University of Technology, Foshan 528225, China.
- Department of pharmacy, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510145, China.
- Department of Medical Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530000, China.
Zitieren
APA
Zhang, S., Zhang, X., Huang, W., Jiang, G., Mo, Y., Wei, L., Fan, P., Chen, M., & Jiang, W. (2024). NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.100188
Vancouver
Zhang S, Zhang X, Huang W, Jiang G, Mo Y, Wei L, et al. NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target. International Journal of Biological Sciences. 2024. doi:10.7150/ijbs.100188
BibTeX
@article{Zhang2024,
author = {Zhang, Shaoping and Zhang, Xiaozhen and Huang, Wenjian and Jiang, Ganling and Mo, Yuanxin and Wei, Liuxia and Fan, Pingming and Chen, Maojian and Jiang, Wei},
title = {NUSAP1 is Upregulated by Estrogen to Promote Lung Adenocarcinoma Growth and Serves as a Therapeutic Target},
journal = {International Journal of Biological Sciences},
year = {2024},
doi = {10.7150/ijbs.100188}
}
EUVIMED